Management of psoriasis and risk and severity of COVID-19 infection in systemic, biologic and topical treatment for psoriasis during the COVID-19 pandemic: an epidemiological cohort study
- Conditions
- Psoriasis1004743810014982
- Registration Number
- NL-OMON51144
- Lead Sponsor
- Bravis Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1500
* Subject is able to sign the informed consent form.
* Age of 18 years or older
* Subject is currently being treated for psoriasis with:
o Conventional systemic immunosuppressive therapy (CSIT) including:
methotrexate, cyclosporin A or fumaric acid. Concomitant topical therapy is
allowed.
o Biological immunosuppressive therapy (BIT) including, but not limited to:
anti IL-17a, anti IL-23 or anti TNF-alpha biological agents. Concomitant
topical therapy is allowed. Combination with low dose MTX is allowed
o Topical therapy (TT) including corticosteroids, anthralin, calcipotriene,
topical vitamin D derivatives, retinoids, urea and medicated shampoos
* Subject is being treated with immunosuppressive therapy for any indication
other than psoriasis
* Subject is incapacitated or otherwise incapable of participating in the
study.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The point-prevalence of COVID-19 infection in the 3 treatment groups<br /><br><br /><br>Risk ratios and confounder corrected odds ratio for treatment with biologics or<br /><br>conventional systemics vs. topical therapies regarding the risk of<br /><br>COVID-infections.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Proportion of severe COVID-19 infection in infected patients in the 3 treatment<br /><br>groups<br /><br>Patient satisfaction with their management by their dermatologist with a visual<br /><br>analogue scale.<br /><br>Patient satisfaction with different modes of teleconsultations with a visual<br /><br>analogue scale.<br /><br>Psoriasis disease activity change during this period on a with a visual<br /><br>analogue scale.<br /><br>Proportions of patients who stayed on treatment, changed treatment or stopped<br /><br>treatment due to Covid-19 infection (fear) with or without consent of their<br /><br>treating dermatologist. </p><br>